Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu JC Biological Technology is a specialized biotechnology company focused on the development and industrialization of recombinant humanized collagen and other bioactive proteins. Utilizing a proprietary synthetic biology platform, the company produces high-purity, non-immunogenic collagen sequences that are identical to human proteins, facilitating superior biocompatibility for medical and aesthetic use. Their product portfolio includes medical-grade raw materials for wound healing, tissue engineering, and dermatology, as well as finished medical devices and functional skincare ingredients. JC Biological Technology operates advanced GMP-compliant manufacturing facilities and is a key player in the rapidly growing field of recombinant biomaterials. The company's research extends to various collagen types and other extracellular matrix proteins to address unmet needs in regenerative medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JC Biological Technology.